Ethical considerations for new HIV prevention trials

Affiliations

¹ Berman Institute of Bioethics, School of Medicine, and Bloomberg School of Public Health, Johns Hopkins University, Baltimore, MD 21205, USA. Electronic address: jsugarman@jhu.edu.
² Global Health, Allergy and Infectious Diseases, University of Washington, Seattle, WA, USA.
³ Vaccine and Infectious Disease Division, Fred Hutchison Cancer Research Center, Seattle, WA, USA.
⁴ Beth Israel Deaconess Medical Center, Harvard Medical School and Fenway Health, Boston, MA, USA.

Jeremy Sugarman et al. Lancet HIV. 2019 Aug.

. 2019 Aug;6(8):e489-e491.

doi: 10.1016/S2352-3018(19)30184-5. Epub 2019 Jun 17.

¹ Berman Institute of Bioethics, School of Medicine, and Bloomberg School of Public Health, Johns Hopkins University, Baltimore, MD 21205, USA. Electronic address: jsugarman@jhu.edu.
² Global Health, Allergy and Infectious Diseases, University of Washington, Seattle, WA, USA.
³ Vaccine and Infectious Disease Division, Fred Hutchison Cancer Research Center, Seattle, WA, USA.
⁴ Beth Israel Deaconess Medical Center, Harvard Medical School and Fenway Health, Boston, MA, USA.

No abstract available

MeSH terms